Transcriptome investigation of anti-inflammation and immuno-regulation mechanism of taurochenodeoxycholic acid.
Animals
Anti-Inflammatory Agents
/ pharmacology
Cystatin B
/ genetics
Glutathione Peroxidase
/ genetics
Immunomodulating Agents
/ pharmacology
Male
Rats, Sprague-Dawley
Serine-Arginine Splicing Factors
/ genetics
Synoviocytes
/ drug effects
Taurochenodeoxycholic Acid
/ pharmacology
Transcriptome
/ drug effects
Fibroblast‐like synoviocytes
Glucocorticoid receptor
RNA sequencing
Serine/arginine-rich splicing factor-9
Taurochenodeoxycholic acid
Journal
BMC pharmacology & toxicology
ISSN: 2050-6511
Titre abrégé: BMC Pharmacol Toxicol
Pays: England
ID NLM: 101590449
Informations de publication
Date de publication:
29 04 2021
29 04 2021
Historique:
received:
31
08
2020
accepted:
19
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Taurochenodeoxycholic acid (TCDCA) is one of the major active components in bile acid. It was proven to have inhibitory activities on inflammation and also participate in host immuno-regulation. TCDCA exerts anti-inflammatory and immuno-regulatory effects through the glucocorticoid receptor (GR) mediated genomic signaling pathway and the G protein-coupled bile acid receptor 5 (TGR5) mediated AC-cAMP-PKA signaling pathway. However, it is unclear whether GR or TGR5 plays an important role in the regulatory effects of TCDCA. In order to further investigate this effects mechanism of TCDCA, the research use the transcriptome to identify the major genes and pathway in the anti-inflammatory and immuno-regulatory effects. After the Fibroblast-like synoviocytes (FLS) being treated by different concentrations (10 Five genes associated with anti-inflammatory and immuno-regulatory effects, include Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Glutathione peroxidase 3 (GPX3), Serine/arginine-rich splicing factor-9 (SRSF9), Connective tissue growth factor (CTGF) and Cystatin B (CSTB) were identified. TCDCA at the concentrations of 10 The anti-inflammatory and immuno-regulatory activities of TCDCA are proven to be related to the up-regulation expression of GPX3, SRSF9 and CSTB.
Sections du résumé
BACKGROUND
Taurochenodeoxycholic acid (TCDCA) is one of the major active components in bile acid. It was proven to have inhibitory activities on inflammation and also participate in host immuno-regulation. TCDCA exerts anti-inflammatory and immuno-regulatory effects through the glucocorticoid receptor (GR) mediated genomic signaling pathway and the G protein-coupled bile acid receptor 5 (TGR5) mediated AC-cAMP-PKA signaling pathway. However, it is unclear whether GR or TGR5 plays an important role in the regulatory effects of TCDCA. In order to further investigate this effects mechanism of TCDCA, the research use the transcriptome to identify the major genes and pathway in the anti-inflammatory and immuno-regulatory effects.
METHODS
After the Fibroblast-like synoviocytes (FLS) being treated by different concentrations (10
RESULTS
Five genes associated with anti-inflammatory and immuno-regulatory effects, include Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Glutathione peroxidase 3 (GPX3), Serine/arginine-rich splicing factor-9 (SRSF9), Connective tissue growth factor (CTGF) and Cystatin B (CSTB) were identified. TCDCA at the concentrations of 10
CONCLUSIONS
The anti-inflammatory and immuno-regulatory activities of TCDCA are proven to be related to the up-regulation expression of GPX3, SRSF9 and CSTB.
Identifiants
pubmed: 33926569
doi: 10.1186/s40360-021-00491-0
pii: 10.1186/s40360-021-00491-0
pmc: PMC8086280
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Immunomodulating Agents
0
Serine-Arginine Splicing Factors
170974-22-8
Taurochenodeoxycholic Acid
516-35-8
Cystatin B
88844-95-5
GPX3 protein, rat
EC 1.11.1.-
Glutathione Peroxidase
EC 1.11.1.9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
23Subventions
Organisme : National Natural Science Foundation of China
ID : NO.31160518
Organisme : Young Scientists Fund
ID : NO.31402248
Références
Eur J Pharmacol. 2013 Apr 15;706(1-3):36-40
pubmed: 23510744
Int Immunopharmacol. 2011 Dec;11(12):2150-8
pubmed: 21983642
Pharmacol Res. 2017 Jun;120:180-187
pubmed: 28373129
Nat Biotechnol. 2014 Sep;32(9):903-14
pubmed: 25150838
Nat Rev Genet. 2009 Jan;10(1):57-63
pubmed: 19015660
Nat Biotechnol. 2015 Mar;33(3):243-6
pubmed: 25748911
Zhong Yao Cai. 2005 Dec;28(12):1089-92
pubmed: 16568667
Nat Methods. 2015 Apr;12(4):357-60
pubmed: 25751142
Ann N Y Acad Sci. 2009 Oct;1179:153-66
pubmed: 19906238
BMC Mol Biol. 2006 Jan 31;7:3
pubmed: 16448564
Cell Signal. 2008 Dec;20(12):2180-97
pubmed: 18634871
Eur J Pharmacol. 2016 Sep 5;786:109-115
pubmed: 27268718
Nat Biotechnol. 2015 Mar;33(3):290-5
pubmed: 25690850
Trends Mol Med. 2012 Jun;18(6):348-59
pubmed: 22578718
J Biol Chem. 2014 Nov 14;289(46):31736-31750
pubmed: 25288807
Tohoku J Exp Med. 2011;224(1):29-39
pubmed: 21512310
Sci Rep. 2016 Jan 11;6:19137
pubmed: 26750705
mSystems. 2019 Sep 10;4(5):
pubmed: 31506261